35 results about "Astragaloside II" patented technology

The present invention discloses a method for preparing astragalus methylglucoside by utilizing enzymatic hydrolysis of astragalus saponin glycosyl. It is characterized by that it uses an enzyme method to hydrolyze astragalus saponin glycosyl to prepare astragalus methylglucoside. The described enzyme is prepared by using astragalus saponin or flavone or isoflavone as fermentation enzyme-producing inductor and utilizing bacteria, streptomycete, mold, saccharomycetes and basidiomycetes to make fermentation. Said invention can be used for preparing astragalus tablet and powder products with high astragalus methylglucoside content.

The invention discloses a drug combination for the treatment of cardiovascular diseases and a preparation method; the active components of the drug combination are extract of ginseng stems and leaves saponin and radix astragali saponin; the drug combination is mainly used in the treatment of coronary heart disease, simultaneously also has a therapeutic effect to the angina caused by lack of myocardial Blood, myocardial infarction, arrhythmias, heart failure and other cardiovascular diseases.

The invention provides application of astragaloside III or its pharmaceutically acceptable salts in the preparation of drugs to promote NK cell amplification, and provides application of astragalosideIII or its pharmaceutically acceptable salts in the preparation of drugs to prevent and/or treat cancers, preferably, lung adenocarcinoma or melanoma. The invention provides application of astragaloside III or its pharmaceutically acceptable salts in the preparation of drugs to prevent and/or treat infectious diseases, and application of astragaloside III or its pharmaceutically acceptable saltsin the preparation of drugs to prevent and/or treat immunological diseases. Astragaloside III or its pharmaceutically acceptable salts can effectively promote NK cell amplification compounds, have theadvantages of small potential toxic and side effects, significant inhibition on cancer cell proliferation, broad-spectrum cancer prevention, good preparation convenience, low cost and the like, and have a promising clinical application prospect.

The invention discloses a Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases, which comprises 35.0-75% of astragalus root saponin extract containing total saponins 70-98%, 0.5-5.0% of tanshinone extract containing tanshinone 55-85%, 15.0-55.0% of total savianolic acid extract containing total savianolic acid 70-98%, 2.5-15.0% of pseudo-ginseng leaf glycosides extract containing total saponins 80-90%, and natural borneol or rosewood oil 2.5-15.0%. The composition has evident functions in resisting cerebral ischemia and myocardial ischemia, the curative effect is better than the application of single extract of tanshinone, total savianolic acid or pseudo-ginseng leaf glycosides, thus providing a more effective and more convenient Chinese medicinal composition and preparation clinically.

The invention discloses a medicament for treating cardiovascular and cerebrovascular diseases, which comprises astragalus root saponin extract 35.0-75%, red sage root extract 15.0-55.0%, panaxtriol saponins extract 2.5-15.0%, and natural borneol or rosewood oil 2.5-15.0%. The content of danshensu in the salvia miltiorrhizae extract is 3-10%, the content of total savianolic acid is 50-75%, the content of salvianolic acid B is 20-45%, the content of total saponins in panaxtriol saponins extract is 80-90%, the content of total saponins in astragalus root saponin extract is 70-98%, the content of Astragaloside IV is 5-15%. The composition has evident functions in resisting cerebral ischemia and myocardial ischemia, the curative effect is better than the application of single extract of red sage root or panaxtriol saponins, thus providing a more effective and more convenient Chinese medicinal composition and preparation clinically.

The invention discloses a Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases, which comprises astragalus root saponin extract 35.0-75%, red sage root extract 15.0-55.0%, pseudo-ginseng saponin extract 2.5-15.0%, and natural borneol or rosewood oil 2.5-15.0%. The content of danshensu in the salvia miltiorrhizae extract is 3-10%, the content of total savianolic acid is 50-75%, the content of salvianolic acid B is 20-45%, the content of total saponins in pseudo-ginseng saponin extract is 70-98%, the content of total saponins in astragalus root saponin extract is 70-98%, the content of Astragaloside IV is 5-15%. The composition has evident functions in resisting cerebral ischemia and myocardial ischemia, the curative effect is better than the application of single extract of red sage root or notoginseng saponin, thus providing a more effective and more convenient Chinese medicinal composition and preparation clinically.

The invention belongs to the technical field of traditional Chinese medicine component detection and provides a method for determining the content of nineteen components in radix stephaniae tetrandraeand astragalus membranaceus soup by ultra-high performance liquid chromatography-tandem mass spectrometry. The method comprises the following steps of pespectively preparing a test solution, a reference solution and a mixed standard solution; detecting the mixed standard substance solution by ultra-high performance liquid chromatography-tandem mass spectrometry, drawing a standard curve and a test solution, performing mass spectrometry positive and negative ion mode analysis by ultra-high performance liquid chromatography-tandem mass spectrometry, and obtaining the contents of nineteen components in the radix stephaniae tetrandrae and astragalus membranaceus soup according to the standard curve. The method is high in sensitivity and good in reproducibility; analysis accuracy and reliability, 19 chemical components in the radix stephaniae tetrandrae and radix astragali soup can be quantitatively detected at the same time; formononetin, formononetin, calycosin-7-one, calycosin-7-one, pterocarpan, pterocarpan, isoflavane, liquiritin, glycyrrhetinic acid, tetrandrine, tetrandrine, atractylodes lactone I, atractylodes lactone II I, isoflavane, astragaloside I, astragaloside II, astragaloside III and astragaloside IV.

The invention relates to a new Chinese medicine for treating early and middle-stage diabetic nephropathy, which is prepared from eight medicinal effect ingredients: astragaloside, astragalan, astragalus flavone, rhubarb total anthraquinone, icraiin, epimedium polysaccharide, ligustrazine and ferulic acid according to a certain ratio. The new Chinese medicine has the specific treatment effect on the early and middle-stage diabetic nephropathy, and can be solid preparations such as tablets, capsules, granules, pills and the like and also can be liquid preparations such as oral liquid, emulsion, microemulsion, injection and the like.

The invention belongs to the technical field of veterinary biological products, and concretely relates to a diluent used for an inactive porcine parvovirus vaccine. Every 1000 ml of a phosphate buffer solution with the pH value of 7 includes 1-5 g of honeysuckle flower and Weeping Forsythia extract, 5-10 g of wolfberry fruit polysaccharides, 20-80 mg of astragaloside II and 1-5 g of polyinosinic-polycytidylic acid. The diluent used for the inactive porcine parvovirus vaccine has the advantages of convenience in production, low cost, convenience and safety in use, reduction of the difference among different batches of vaccines, and improvement of the integral immunizing effect of the vaccine.

The invention discloses bacillus licheniformis and application thereof, and belongs to the technical field of biological fermentation and biotransformation. The bacillus licheniformis LZZT-002 disclosed by the invention has xylanase activity and cellulase activity, and can improve the yield of astragalus polysaccharide, astragalus saponin and derivatives thereof when being used for fermentation and transformation of an astragalus extract. A fermented radix astragali feed additive prepared by fermenting radix astragali through the strain LZZT-002 is an efficient microbial agent integrating probiotics and effective components of traditional Chinese medicines, has the characteristics of environmental friendliness, excellent performance and the like, and has good economic and social benefits.

The invention discloses astragaloside III nanoparticles traced by dihydroporphin fluorescence and a preparation method thereof. Mesoporous silica particles are used as a carrier to adjust the ratio ofan encapsulated dihydroporphin fluorescent dye and an astragaloside III drug to control the drug loading rate of the nanoparticles and prepare the drug-loaded nanoparticles with the particle size of80-100 nm. The dihydroporphin fluorescent dye and the astragaloside III are simultaneously encapsulated in the mesoporous silica nanoparticles to achieve both therapeutic and imaging functions. The nanoparticles can be efficiently phagocytized by tumor cells, and the problem of high clearance rate of a drug in vivo is solved. The position of the drug can be traced in real time by observing the dihydroporphin fluorescence distribution in the nano-carrier.

The invention discloses an astragalus functional food with an effect of improving alcoholic liver injury, the main functional component of the functional food is astragalus polysaccharide or/and astragaloside, and the extraction method mainly adopts an ultrasonic-assisted ethanol extraction method. The functional food is prepared by the following steps: weighing astragalus polysaccharide or/and astragaloside and other auxiliary materials in proportion, blending, sterilizing, granulating, tabletting, packaging and the like. The functional food can be prepared into tablets, oral liquid, capsules, electuary, leisure food or beverage and the like, and has the effect of remarkably improving alcoholic liver injury.

The invention relates to a process of a preparation method of an anti-aging cell telomerase active agent. The preparation method comprises the following steps: (1) taking 500g of astragalus membranaceus fine powder; (2) putting the astragalus membranaceus fine powder into an HWC-3 microwave extraction equipment instrument, performing microwave heating, performing extraction for three times by using an alcohol and water extraction method, controlling the heating power of the microwave extraction equipment to be 500w-1000w, controlling the temperature to be 70-75 DEG C/C, performing alcohol extraction twice, adding ethanol which is 5 times of the mass of 70-90% of the micro powder for the first time, performing reaction extraction for 20-30 minutes, adding 75-95% ethanol which is 5 times of the mass of the micro powder for the second time, and (3) concentrating the secondary ethanol extracting solution, removing ethanol, adding distilled water which is 10 times of the mass of the astragalus membranaceus micro powder for the third time, heating at 70-75 DEG C/C, reacting for 2 hours, standing for 24 hours, recovering the concentrate from the supernate, and carrying out vacuum drying for 48 hours to obtain an astragaloside active matter crystal. The extraction process method shortens the reaction extraction time, the extraction process is energy-saving and efficient, and the utilization rate of effective components is high.

The invention relates to an application of an extract of a medicinal natural product, in particular to an application of a radix astragali extract. The natural product extract disclosed by the invention is an extract of radix astragali, especially total flavonoids of radix astragali or astragaloside. The radix astragali extract disclosed by the invention can be directly used for preparing the medicine for treating the pulmonary fibrosis disease or used for preparing the compound medicine for treating the pulmonary fibrosis disease. The invention has the following beneficial effects: 1, it is found for the first time that total flavonoids of radix astragali and astragaloside can inhibit polarization of M2 type macrophages and activation of TGF-beta1/Smads signal channels, and effectively inhibit pulmonary fibrosis; and 2, the medicine is a traditional Chinese medicinal material, is low in price and small in toxic and side effects, can remarkably inhibit the development of pulmonary fibrosis, and is worthy of wide popularization.

The invention belongs to the technical field of chemical induction of traditional Chinese medicine radix astragali adventitious roots, and provides a chemical inducer for radix astragali adventitious root tissue culture and application of the chemical inducer in radix astragali adventitious root culture in order to solve the problems of green and sustainable development of radix astragali resources at present. Cis-3-hexenal is dissolved in water to prepare a mother solution with the concentration of 200 mmol/L, and the mother solution is stored at the temperature of 4 DEG C for standby application after being filtered and sterilized by a sterile filter membrane. The growth of the radix astragali adventitious roots and the synthesis and accumulation of triterpenes and isoflavone active ingredients are promoted in a dose-dependent manner, so that the browning of radix astragali adventitious root culture is inhibited; and synthesis and accumulation of astragaloside I, isoastragaloside I, astragaloside II, astragaloside III, cycloastragaloside II, liquiritin, formononin, calycosin, glucoside of calycosin and the like in the roots are promoted. The additive is expected to be developed into a green additive which is applied to an astragalus mongholicus adventitious root tissue culture system to improve the yield of root culture and the content of active substances.

The invention belongs to the technical field of biology, and discloses a new application of isoastragaloside II in preparation of tumor immune treatment drugs. The embodiment proves that the isoastragaloside II promotes CD8 + T cells to be differentiated into CTL cells, the characteristic of killing tumor cells is achieved, and the isoastragaloside II does not have cytotoxicity, so that the isoastragaloside II can be applied to preparation of tumor immune treatment drugs.